Details of the Drug

General Information of Drug (ID: DM0762O)

Drug Name
Fenfluramine
Synonyms
Acino; Adifax; Adipomin; Fenfluramina; Fenfluraminum; Isomeride; Obedrex; Pesos; Ponderex; Rotondin; Dexfenfluramina [Spanish]; Dexfenfluraminum [Latin]; Fenfluramina [DCIT]; Fenfluramine hydrochloride; Levofenfluramine [INN]; Ponderax PA; S 768; D-Fenfluramine; Dexfenfluramine [INN:BAN]; Fenfluramine (INN); Fenfluramine [INN:BAN]; Fenfluraminum [INN-Latin]; Ponderax (TN); Fenfluramine, (+-)-Isomer; N-Ethyl-alpha-methyl-3-trifluoromethylphenethylamine; D-N-Ethyl-alpha-methyl-m-trifluoromethylphenethylamine; N-Ethyl-alpha-methyl-3-(trifluoromethyl)benzeneethanamine; N-Ethyl-alpha-methyl-m-(trifluoromethyl)phenethylamine; N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine; Benzeneethanamine, N-ethyl-alpha-methyl-3-(trifluoromethyl)-(9CI); Benzeneethanamine, N-ethyl-alpha-methyl-3-(trifluoromethyl)-, (S)-(9CI);Benzeneethanamine, N-ethyl-alpha-methyl-3-(trifluoromethyl)-, (+-)-(9CI); (+)-Fenfluramine; (+-)-Fenfluramine; (+/-)-Fenfluramine hydrochloride; (S)-Fenfluramine; 1-(m-trifluoromethyl-phenyl)-2-ethylaminopropane; 1-(meta-Trifluoromethyl-phenyl)-2 ethylaminopropane; 2-Ethylamino-1-(3-trifluoromethylphenyl)propane; 3-(Trifluoromethyl)-N-ethyl-alpha-methylphenethylamine
Indication
Disease Entry ICD 11 Status REF
Dravet syndrome 8A61.11 Phase 3 [1]
LennoxGastaut syndrome 8A62.1 Phase 3 [1]
Obesity 5B81 Withdrawn from market [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 231.26
Logarithm of the Partition Coefficient (xlogp) 3.4
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 4-5 h [3]
Bioavailability
The bioavailability of drug is 68-74% [3]
Clearance
The clearance of drug is 24.8 L/h [3]
Elimination
Over 90% of fenfluramine is excreted in urine and less than 5% in feces [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 20 hours [3]
Metabolism
The drug is metabolized via the liver [3]
Vd
The volume of distribution (Vd) of drug is 11.9 L/kg [3]
Chemical Identifiers
Formula
C12H16F3N
IUPAC Name
N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine
Canonical SMILES
CCNC(C)CC1=CC(=CC=C1)C(F)(F)F
InChI
InChI=1S/C12H16F3N/c1-3-16-9(2)7-10-5-4-6-11(8-10)12(13,14)15/h4-6,8-9,16H,3,7H2,1-2H3
InChIKey
DBGIVFWFUFKIQN-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3337
ChEBI ID
CHEBI:5000
CAS Number
458-24-2
DrugBank ID
DB00574
TTD ID
D09WNK
VARIDT ID
DR00583
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT receptor (5HTR) TT85JO3 NOUNIPROTAC Antagonist [4]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
5-hydroxytryptamine receptor 2A (HTR2A) OTWXJX0M 5HT2A_HUMAN Protein Interaction/Cellular Processes [5]
5-hydroxytryptamine receptor 2B (HTR2B) OTM1AD9J 5HT2B_HUMAN Drug Response [6]
5-hydroxytryptamine receptor 2C (HTR2C) OT6H8DE0 5HT2C_HUMAN Protein Interaction/Cellular Processes [5]
Acid ceramidase (ASAH1) OT1DNGXL ASAH1_HUMAN Gene/Protein Processing [7]
Angiopoietin-related protein 4 (ANGPTL4) OTQL5SPX ANGL4_HUMAN Gene/Protein Processing [7]
Bone morphogenetic protein receptor type-2 (BMPR2) OTM9W547 BMPR2_HUMAN Drug Response [8]
Coiled-coil domain-containing protein 62 (CCDC62) OTTIAOBP CCD62_HUMAN Gene/Protein Processing [7]
Cytoplasmic dynein 2 heavy chain 1 (DYNC2H1) OTLC8K6B DYHC2_HUMAN Gene/Protein Processing [7]
Dedicator of cytokinesis protein 8 (DOCK8) OTNQLL21 DOCK8_HUMAN Gene/Protein Processing [7]
Dickkopf-like protein 1 (DKKL1) OTWS7DED DKKL1_HUMAN Gene/Protein Processing [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Fenfluramine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Major Additive serotonergic effects by the combination of Fenfluramine and Methylene blue. Acquired methaemoglobinaemia [3A93] [9]
Oliceridine DM6MDCF Moderate Additive CNS depression effects by the combination of Fenfluramine and Oliceridine. Acute pain [MG31] [10]
Donepezil DMIYG7Z Minor Decreased metabolism of Fenfluramine caused by Donepezil mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [11]
Inotersen DMJ93CT Moderate Increased risk of bleeding by the combination of Fenfluramine and Inotersen. Amyloidosis [5D00] [12]
Cilostazol DMZMSCT Moderate Increased risk of bleeding by the combination of Fenfluramine and Cilostazol. Arterial occlusive disease [BD40] [12]
Desipramine DMT2FDC Moderate Additive serotonergic effects by the combination of Fenfluramine and Desipramine. Attention deficit hyperactivity disorder [6A05] [13]
Droxidopa DM5YF4M Moderate Additive hypertensive effects by the combination of Fenfluramine and Droxidopa. Autonomic nervous system disorder [8D87] [14]
Tamoxifen DMLB0EZ Major Decreased metabolism of Fenfluramine caused by Tamoxifen mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [15]
Trastuzumab Emtansine DMU1LXS Moderate Increased risk of bleeding by the combination of Fenfluramine and Trastuzumab Emtansine. Breast cancer [2C60-2C6Y] [16]
Phenylbutazone DMAYL0T Moderate Increased risk of bleeding by the combination of Fenfluramine and Phenylbutazone. Chronic pain [MG30] [12]
Dihydrocodeine DMB0FWL Moderate Additive serotonergic effects by the combination of Fenfluramine and Dihydrocodeine. Chronic pain [MG30] [10]
Ketoprofen DMRKXPT Moderate Increased risk of bleeding by the combination of Fenfluramine and Ketoprofen. Chronic pain [MG30] [12]
Levomilnacipran DMV26S8 Major Additive serotonergic effects by the combination of Fenfluramine and Levomilnacipran. Chronic pain [MG30] [17]
Anisindione DM2C48U Moderate Increased risk of bleeding by the combination of Fenfluramine and Anisindione. Coagulation defect [3B10] [12]
Regorafenib DMHSY1I Moderate Increased risk of bleeding by the combination of Fenfluramine and Regorafenib. Colorectal cancer [2B91] [12]
Alfentanil DMVO0UB Major Additive serotonergic effects by the combination of Fenfluramine and Alfentanil. Corneal disease [9A76-9A78] [17]
Remifentanil DMZTXCH Major Additive serotonergic effects by the combination of Fenfluramine and Remifentanil. Corneal disease [9A76-9A78] [17]
Ardeparin DMYRX8B Moderate Increased risk of bleeding by the combination of Fenfluramine and Ardeparin. Coronary thrombosis [BA43] [12]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Fenfluramine and Ethanol. Cystitis [GC00] [18]
Danaparoid DM6CLBN Moderate Increased risk of bleeding by the combination of Fenfluramine and Danaparoid. Deep vein thrombosis [BD71] [12]
Rivaroxaban DMQMBZ1 Moderate Increased risk of bleeding by the combination of Fenfluramine and Rivaroxaban. Deep vein thrombosis [BD71] [12]
Sertraline DM0FB1J Major Additive serotonergic effects by the combination of Fenfluramine and Sertraline. Depression [6A70-6A7Z] [17]
Trimipramine DM1SC8M Moderate Decreased metabolism of Fenfluramine caused by Trimipramine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [13]
Cyclobenzaprine DM1YBRM Major Additive serotonergic effects by the combination of Fenfluramine and Cyclobenzaprine. Depression [6A70-6A7Z] [17]
Vilazodone DM4LECQ Major Additive serotonergic effects by the combination of Fenfluramine and Vilazodone. Depression [6A70-6A7Z] [17]
Nefazodone DM4ZS8M Major Additive serotonergic effects by the combination of Fenfluramine and Nefazodone. Depression [6A70-6A7Z] [17]
Paroxetine DM5PVQE Major Additive serotonergic effects by the combination of Fenfluramine and Paroxetine. Depression [6A70-6A7Z] [17]
Selegiline DM6034S Major Additive serotonergic effects by the combination of Fenfluramine and Selegiline. Depression [6A70-6A7Z] [19]
Vortioxetine DM6F1PU Major Additive serotonergic effects by the combination of Fenfluramine and Vortioxetine. Depression [6A70-6A7Z] [17]
Isocarboxazid DMAF1NB Major Additive serotonergic effects by the combination of Fenfluramine and Isocarboxazid. Depression [6A70-6A7Z] [19]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of Fenfluramine and Milnacipran. Depression [6A70-6A7Z] [17]
Escitalopram DMFK9HG Major Additive serotonergic effects by the combination of Fenfluramine and Escitalopram. Depression [6A70-6A7Z] [17]
Tranylcypromine DMGB5RE Major Additive serotonergic effects by the combination of Fenfluramine and Tranylcypromine. Depression [6A70-6A7Z] [19]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Fenfluramine and Desvenlafaxine. Depression [6A70-6A7Z] [17]
Phenelzine DMHIDUE Major Additive serotonergic effects by the combination of Fenfluramine and Phenelzine. Depression [6A70-6A7Z] [19]
Clomipramine DMINRKW Moderate Additive serotonergic effects by the combination of Fenfluramine and Clomipramine. Depression [6A70-6A7Z] [13]
Trazodone DMK1GBJ Major Additive serotonergic effects by the combination of Fenfluramine and Trazodone. Depression [6A70-6A7Z] [17]
Doxepin DMPI98T Moderate Additive serotonergic effects by the combination of Fenfluramine and Doxepin. Depression [6A70-6A7Z] [13]
Maprotiline DMPWB7T Major Additive serotonergic effects by the combination of Fenfluramine and Maprotiline. Depression [6A70-6A7Z] [17]
Esketamine DMVU687 Major Additive hypertensive effects by the combination of Fenfluramine and Esketamine. Depression [6A70-6A7Z] [20]
5-hydroxy-L-tryptophan DMDWZGJ Major Additive serotonergic effects by the combination of Fenfluramine and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [21]
Mefenamic acid DMK7HFI Moderate Increased risk of bleeding by the combination of Fenfluramine and Mefenamic acid. Female pelvic pain [GA34] [12]
Tazemetostat DMWP1BH Moderate Increased risk of bleeding by the combination of Fenfluramine and Tazemetostat. Follicular lymphoma [2A80] [12]
Mirabegron DMS1GYT Moderate Decreased metabolism of Fenfluramine caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [22]
Tolterodine DMSHPW8 Minor Decreased metabolism of Fenfluramine caused by Tolterodine mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [23]
Terbinafine DMI6HUW Moderate Decreased metabolism of Fenfluramine caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [24]
Avapritinib DMK2GZX Moderate Increased risk of bleeding by the combination of Fenfluramine and Avapritinib. Gastrointestinal stromal tumour [2B5B] [12]
Sulfinpyrazone DMEV954 Moderate Increased risk of bleeding by the combination of Fenfluramine and Sulfinpyrazone. Gout [FA25] [12]
Ergotamine DMKR3C5 Major Additive serotonergic effects by the combination of Fenfluramine and Ergotamine. Headache [8A80-8A84] [17]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Fenfluramine caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [25]
Dipyridamole DMXY30O Moderate Increased risk of bleeding by the combination of Fenfluramine and Dipyridamole. Hypertension [BA00-BA04] [12]
Givosiran DM5PFIJ Moderate Decreased metabolism of Fenfluramine caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [26]
Meclofenamic acid DM05FXR Moderate Increased risk of bleeding by the combination of Fenfluramine and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [16]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Fenfluramine caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [27]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Fenfluramine and Polyethylene glycol. Irritable bowel syndrome [DD91] [28]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Fenfluramine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [29]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Fenfluramine caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [30]
Acalabrutinib DM7GCVW Moderate Increased risk of bleeding by the combination of Fenfluramine and Acalabrutinib. Mature B-cell lymphoma [2A85] [12]
Ibrutinib DMHZCPO Moderate Increased risk of bleeding by the combination of Fenfluramine and Ibrutinib. Mature B-cell lymphoma [2A85] [12]
Ponatinib DMYGJQO Moderate Increased risk of bleeding by the combination of Fenfluramine and Ponatinib. Mature B-cell lymphoma [2A85] [12]
Vemurafenib DM62UG5 Moderate Decreased metabolism of Fenfluramine caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [31]
Almogran DM7I64Z Major Additive serotonergic effects by the combination of Fenfluramine and Almogran. Migraine [8A80] [17]
Frovatriptan DM7RE8P Major Additive serotonergic effects by the combination of Fenfluramine and Frovatriptan. Migraine [8A80] [17]
Rizatriptan DMDJMA3 Major Additive serotonergic effects by the combination of Fenfluramine and Rizatriptan. Migraine [8A80] [17]
Naratriptan DMO50U2 Major Additive serotonergic effects by the combination of Fenfluramine and Naratriptan. Migraine [8A80] [17]
Sumatriptan DMVYXR8 Major Additive serotonergic effects by the combination of Fenfluramine and Sumatriptan. Migraine [8A80] [17]
Exjade DMHPRWG Moderate Increased risk of bleeding by the combination of Fenfluramine and Exjade. Mineral absorption/transport disorder [5C64] [12]
Panobinostat DM58WKG Major Increased risk of bleeding by the combination of Fenfluramine and Panobinostat. Multiple myeloma [2A83] [12]
Ozanimod DMT6AM2 Moderate Additive serotonergic effects by the combination of Fenfluramine and Ozanimod. Multiple sclerosis [8A40] [19]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Fenfluramine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [29]
Ruxolitinib DM7Q98D Moderate Increased risk of bleeding by the combination of Fenfluramine and Ruxolitinib. Myeloproliferative neoplasm [2A20] [12]
Imatinib DM7RJXL Moderate Decreased metabolism of Fenfluramine caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [32]
Dasatinib DMJV2EK Moderate Increased risk of bleeding by the combination of Fenfluramine and Dasatinib. Myeloproliferative neoplasm [2A20] [12]
Prasugrel DM7MT6E Moderate Increased risk of bleeding by the combination of Fenfluramine and Prasugrel. Myocardial infarction [BA41-BA43] [12]
Vorapaxar DMA16BR Moderate Increased risk of bleeding by the combination of Fenfluramine and Vorapaxar. Myocardial infarction [BA41-BA43] [12]
Tirofiban DMQG17S Moderate Increased risk of bleeding by the combination of Fenfluramine and Tirofiban. Myocardial infarction [BA41-BA43] [12]
Rolapitant DM8XP26 Moderate Decreased metabolism of Fenfluramine caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [33]
Granisetron DMIUW25 Major Additive serotonergic effects by the combination of Fenfluramine and Granisetron. Nausea/vomiting [MD90] [34]
Dolasetron DMMG26Z Major Additive serotonergic effects by the combination of Fenfluramine and Dolasetron. Nausea/vomiting [MD90] [34]
Ondansetron DMOTQ1I Major Additive serotonergic effects by the combination of Fenfluramine and Ondansetron. Nausea/vomiting [MD90] [34]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Fenfluramine and Bupropion. Nicotine use disorder [6C4A] [34]
Levomethadyl Acetate DM06HG5 Moderate Additive CNS depression effects by the combination of Fenfluramine and Levomethadyl Acetate. Opioid use disorder [6C43] [10]
Diclofenac DMPIHLS Moderate Increased risk of bleeding by the combination of Fenfluramine and Diclofenac. Osteoarthritis [FA00-FA05] [12]
Naproxen DMZ5RGV Moderate Increased risk of bleeding by the combination of Fenfluramine and Naproxen. Osteoarthritis [FA00-FA05] [12]
Pentazocine DM1XBHS Major Additive serotonergic effects by the combination of Fenfluramine and Pentazocine. Pain [MG30-MG3Z] [17]
Butorphanol DM5KYPJ Moderate Additive serotonergic effects by the combination of Fenfluramine and Butorphanol. Pain [MG30-MG3Z] [10]
Oxymorphone DM65AGJ Moderate Additive CNS depression effects by the combination of Fenfluramine and Oxymorphone. Pain [MG30-MG3Z] [10]
Aspirin DM672AH Moderate Increased risk of bleeding by the combination of Fenfluramine and Aspirin. Pain [MG30-MG3Z] [16]
Etodolac DM6WJO9 Moderate Increased risk of bleeding by the combination of Fenfluramine and Etodolac. Pain [MG30-MG3Z] [12]
Diflunisal DM7EN8I Moderate Increased risk of bleeding by the combination of Fenfluramine and Diflunisal. Pain [MG30-MG3Z] [12]
Ibuprofen DM8VCBE Moderate Increased risk of bleeding by the combination of Fenfluramine and Ibuprofen. Pain [MG30-MG3Z] [12]
Levorphanol DMGS80V Moderate Additive CNS depression effects by the combination of Fenfluramine and Levorphanol. Pain [MG30-MG3Z] [10]
Dezocine DMJDB0Y Moderate Additive serotonergic effects by the combination of Fenfluramine and Dezocine. Pain [MG30-MG3Z] [10]
Nalbuphine DMOSQGU Moderate Additive CNS depression effects by the combination of Fenfluramine and Nalbuphine. Pain [MG30-MG3Z] [10]
Buprenorphine DMPRI8G Moderate Additive serotonergic effects by the combination of Fenfluramine and Buprenorphine. Pain [MG30-MG3Z] [10]
Hydrocodone DMQ2JO5 Moderate Additive CNS depression effects by the combination of Fenfluramine and Hydrocodone. Pain [MG30-MG3Z] [10]
Safinamide DM0YWJC Major Additive serotonergic effects by the combination of Fenfluramine and Safinamide. Parkinsonism [8A00] [19]
Rasagiline DM3WKQ4 Major Additive serotonergic effects by the combination of Fenfluramine and Rasagiline. Parkinsonism [8A00] [19]
Choline salicylate DM8P137 Moderate Increased risk of bleeding by the combination of Fenfluramine and Choline salicylate. Postoperative inflammation [1A00-CA43] [12]
Bromfenac DMKB79O Moderate Increased risk of bleeding by the combination of Fenfluramine and Bromfenac. Postoperative inflammation [1A00-CA43] [12]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Fenfluramine caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [35]
Tamsulosin DM5QF9V Moderate Decreased metabolism of Fenfluramine caused by Tamsulosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [36]
Epoprostenol DMUTYR2 Moderate Increased risk of bleeding by the combination of Fenfluramine and Epoprostenol. Pulmonary hypertension [BB01] [12]
Iloprost DMVPZBE Moderate Increased risk of bleeding by the combination of Fenfluramine and Iloprost. Pulmonary hypertension [BB01] [12]
Meloxicam DM2AR7L Moderate Increased risk of bleeding by the combination of Fenfluramine and Meloxicam. Rheumatoid arthritis [FA20] [12]
Sulindac DM2QHZU Moderate Increased risk of bleeding by the combination of Fenfluramine and Sulindac. Rheumatoid arthritis [FA20] [12]
Oxaprozin DM9UB0P Moderate Increased risk of bleeding by the combination of Fenfluramine and Oxaprozin. Rheumatoid arthritis [FA20] [12]
Flurbiprofen DMGN4BY Moderate Increased risk of bleeding by the combination of Fenfluramine and Flurbiprofen. Rheumatoid arthritis [FA20] [12]
Thioridazine DM35M8J Major Decreased metabolism of Fenfluramine caused by Thioridazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [37]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Fenfluramine caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [38]
Salicyclic acid DM2F8XZ Moderate Increased risk of bleeding by the combination of Fenfluramine and Salicyclic acid. Seborrhoeic dermatitis [EA81] [16]
Fentanyl DM8WAHT Major Additive serotonergic effects by the combination of Fenfluramine and Fentanyl. Sensation disturbance [MB40] [17]
Sufentanil DMU7YEL Major Additive serotonergic effects by the combination of Fenfluramine and Sufentanil. Sensation disturbance [MB40] [17]
Pitolisant DM8RFNJ Moderate Decreased metabolism of Fenfluramine caused by Pitolisant mediated inhibition of CYP450 enzyme. Somnolence [MG42] [29]
Warfarin DMJYCVW Moderate Increased risk of bleeding by the combination of Fenfluramine and Warfarin. Supraventricular tachyarrhythmia [BC81] [12]
Caplacizumab DMPUKA7 Moderate Increased risk of bleeding by the combination of Fenfluramine and Caplacizumab. Thrombocytopenia [3B64] [12]
Apixaban DM89JLN Moderate Increased risk of bleeding by the combination of Fenfluramine and Apixaban. Thrombosis [DB61-GB90] [12]
Cangrelor DM8JRH0 Moderate Increased risk of bleeding by the combination of Fenfluramine and Cangrelor. Thrombosis [DB61-GB90] [12]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Fenfluramine and Brilinta. Thrombosis [DB61-GB90] [12]
Clopidogrel DMOL54H Moderate Increased risk of bleeding by the combination of Fenfluramine and Clopidogrel. Thrombosis [DB61-GB90] [12]
Cabozantinib DMIYDT4 Moderate Increased risk of bleeding by the combination of Fenfluramine and Cabozantinib. Thyroid cancer [2D10] [12]
Betrixaban DM2C4RF Moderate Increased risk of bleeding by the combination of Fenfluramine and Betrixaban. Venous thromboembolism [BD72] [12]
⏷ Show the Full List of 122 DDI Information of This Drug

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4613).
3 FDA Approved Drug Products: Fintepla (fenfluramine) oral solution
4 Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418.
5 Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol. 2000 Jan;57(1):75-81.
6 Serotonin 5-HT(2B) receptor loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension. Cardiovasc Res. 2003 Dec 1;60(3):518-28. doi: 10.1016/j.cardiores.2003.09.015.
7 Fenfluramine-induced gene dysregulation in human pulmonary artery smooth muscle and endothelial cells. Pulm Circ. 2011 Jul-Sep;1(3):405-18. doi: 10.4103/2045-8932.87310.
8 BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J. 2002 Sep;20(3):518-23. doi: 10.1183/09031936.02.01762002.
9 Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
10 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
11 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
12 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
13 Fogelson DL "Fenfluramine and the cytochrome P450 system." Am J Psychiatry 154 (1997): 436-7. [PMID: 9054800]
14 Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
15 Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51. [PMID: 11304901]
16 Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6. [PMID: 2530759]
17 Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
18 Product Information. Suprenza (phentermine). Akrimax Pharmaceuticals, Cranford, NJ.
19 Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
20 Cerner Multum, Inc. "Australian Product Information.".
21 Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
22 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
23 Brynne N, Svanstrom C, AbergWistedt A, Hallen B, Bertilsson L "Fluoxetine inhibits the metabolism of tolterodin-pharmacokinetic implications and proposed clinical relevance." Br J Clin Pharmacol 48 (1999): 553-63. [PMID: 10583026]
24 AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
25 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
26 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
27 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
28 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
29 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
30 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
31 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
32 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
33 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
34 Canadian Pharmacists Association.
35 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
36 Franco-Salinas G, de la Rosette JJ, Michel MC "Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations." Clin Pharmacokinet 49 (2010): 177-88. [PMID: 20170206]
37 Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
38 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.